Inducibility of CYP1A2 by omeprazole in vivo related to the genetic polymorphism of CYP1A2

British Journal of Clinical Pharmacology

Volumn 54, Issue 5, 2002, Pages 540-543

  Han, Xing Mei ^a   Ouyang, Dong Sheng ^a   Chen, Xiao Ping ^a   Shu, Yan ^a   Jiang, Chang Hong ^a   Tan, Zhi Rong ^a   Zhou, Hong Hao ^a  

^a Central South University   (China)

Author keywords

Caffeine; CYP1A2; Genetic polymorphism; Induction

Indexed keywords

CAFFEINE; CYTOCHROME P450 1A2; OMEPRAZOLE; PARAXANTHINE;

ADULT; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; MALE; NORMAL HUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN INDUCTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADULT; CAFFEINE; CYTOCHROME P-450 CYP1A2; ENZYME INHIBITORS; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; OMEPRAZOLE; PHOSPHODIESTERASE INHIBITORS; POLYMORPHISM, GENETIC;

EID: 0036433001     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2002.01686.x     Document Type: Article

References (14)

1. Xu ZH, Zhou HH. Cytochrome P450 1A2 in drug metabolism. J Clin Pharmacol 1996; 12: 115-121.
2. Han XM, Zhou HH. Polymorphism of CYP450 and cancer susceptibility. Acta Pharmacol Sin 2000; 21: 673-679.
3. Ouyang DS, Huang SL, Wang W, Xie HG, Xu ZH, Zhou HH. Phenotypic polymorphism and gender-related differences of CYP1A2 activity in a Chinese population. Br J Clin Pharmacol 2000; 49: 145-151.
4. Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, Kamataki T. Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: Effect on the CYP1A2 inducibility in humans. J Biochem (Tokyo) 1999; 125: 803-808.
5. iúA polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999; 47: 445-449.
6. Chida M, Yokoi T, Fukui T, Kinoshita M, Yokota J, Kamataki T. Detection of three genetic polymorphisms in the 5′-flanking region and intron 1 of human CYP1A2 in the Japanese population. Jpn J Cancer Res 1999; 90: 899-902.
7. Han XM, Chen XP, Wu QN, Jiang CH, Zhou HH. G-2964A and C734A genetic polymorphisms of CYP1A2 in Chinese population. Acta Pharmacol Sin 2000; 21: 1031-1034.
8. Han XM, OuYang DS, Lu PX, et al. Plasma caffeine metabolite ratio (17X/137X) invivo associated with G-2964A and C734A polymorphisms of human CYP1A2. Pharmacogenetics 2001; in press.
9. Shu Y, Zhou HH. Individual and ethnic differences in CYP2C19 activity in Chinese populations. Acta Pharmacol Sin 2000; 21: 193-199.
10. Andersson T, Regardh CG, Dahl-Puustinen ML, Bertilsson L. Slow omeprazole metabolizers are also poor S-mephentoin hydroxylators. Ther Drug Monit 1990;12: 415-416.
11. Rost KL, Brosicke H, Heinemeyer G, Roots I. Specific and dose-dependent enzyme induction in human beings. Hepatology 1994; 20: 1204-1212.
12. Rost KL, Roots I. Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: Coincidence with plasma clearance and breath test. Clin Pharmacol Ther 1994; 55: 402-411.
13. Parkinson A, Hurwitz A. Omeprazole and the induction of human cytochrome P-450: A response to concerns about potential adverse effects. Gastroenterology 1991; 100: 1157-1164.
14. Sarich T, Kalhorn T, Magee S,et al. The effect of omeprazole pretreatment on acetaminophen metabolism in rapid and slow metabolizers of S-mephenytoin. Clin Pharmacol Ther 1997; 62: 21-28.